Contact A Counsellor

counsellor button


Research on Depression in the Workplace.

For more information please click here



To subscribe to SADAG's newsletter, click here

To view previous newsletters - click here


Mental Health Matters Journal for Psychiatrists & GP's

MHM Volume 7 Issue1 small

Click here for more info on articles & how to subscribe


cope with cancer book

Literacy is a luxury that many of us take for granted.  We depend on written communication for information, guidance, and access to heath care information That is why SADAG created SPEAKING BOOKS and revolutionized the way information is delivered to low literacy communities. It's exactly what it sounds like.a book that talks to the reader in his or her local  language, delivering critical information in an interactive, and educational way.

The customizable 16-page book, accompanied by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood..

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 30 titles, such as TB, Malaria, Polio, Vaccines for over 30 countries.

suicide speaking book

Antidepressant Combination Therapy in Initial Depression Management

Leslie Citrome, MD, MPH

Posted: 03/22/2010

Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study

Blier P, Ward HE, Tremblay P, Laberge L, H??bert C, Bergeron R
Am J Psychiatry. 2010;167:281-288


In this double-blind study, 105 participants initiating treatment for major depressive disorder were randomly assigned to receive fluoxetine monotherapy (20 mg/day) or mirtazapine (30 mg/day) in combination with fluoxetine (20 mg/day), venlafaxine (225 mg/day titrated in 14 days), or bupropion (150 mg/day) for 6 weeks. The primary outcome measure was the Hamilton Depression Rating Scale (HAM-D) score. Compared with fluoxetine monotherapy, all 3 combination groups had significantly greater improvements on the HAM-D. Remission rates (defined as a HAM-D score of 7 or less) were 25% for fluoxetine, 52% for mirtazapine plus fluoxetine, 58% for mirtazapine plus venlafaxine, and 46% for mirtazapine plus bupropion. Among patients who had a marked response, double-blind discontinuation of 1 agent produced a relapse in about 40% of cases. The combination treatments were as well tolerated as fluoxetine monotherapy.


The study authors note that the use of mirtazapine in combination with another antidepressant may double the likelihood of remission compared with use of a single medication. Remission is the holy grail of treatment because it greatly decreases the risk for relapse. Therefore, the use of antidepressant medication combinations from day 1 may represent a significant advance in the treatment of major depressive disorder. There are several caveats, however. Although the number needed to treat to encounter 1 additional remitted patient was as strong as 3 for the comparison of fluoxetine vs mirtazapine plus venlafaxine, time to response and time to remission was the same for monotherapy as it was for combination treatment. In addition, fluoxetine monotherapy was at a fixed dose of 20 mg/day, with no provision for adjustment upwards. A remaining unknown factor is the potential utility of combination treatment for patients in their first major depressive episode vs those who have experienced multiple episodes and varying histories of therapeutic response. A practical obstacle is the need to prescribe 2 medications. The development of a combination pill would be a possible solution.


Our Sponsors

Our Partners